RESUMEN
Background: The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). The Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS), based on classical clinical parameters, has outperformed the IPSS, revised version (IPSS-R). For the first time, we validated the IPSS-M and other molecular prognostic models and compared them with the established IPSS-R and AIPSS-MDS models using data from South American patients. Methods: Molecular and clinical data from 145 patients with MDS and 37 patients with MDS/myeloproliferative neoplasms were retrospectively analyzed. Results: Prognostic power evaluation revealed that the IPSS-M (Harrell's concordance [C]-index: 0.75, area under the receiver operating characteristic curve [AUC]: 0.68) predicted overall survival better than the European MDS (EuroMDS; C-index: 0.72, AUC: 0.68) and Munich Leukemia Laboratory (MLL) (C-index: 0.70, AUC: 0.64) models. The IPSS-M prognostic discrimination was similar to that of the AIPSS-MDS model (C-index: 0.74, AUC: 0.66) and outperformed the IPSS-R model (C-index: 0.70, AUC: 0.61). Considering simplified low- and high-risk groups for clinical management, after restratifying from IPSS-R (57% and 32%, respectively, hazard ratio [HR]: 2.8; P=0.002) to IPSS-M, 12.6% of patients were upstaged, and 5% were downstaged (HR: 2.9; P=0.001). The AIPSS-MDS recategorized 51% of the low-risk cohort as high-risk, with no patients being downstaged (HR: 5.6; P<0.001), consistent with most patients requiring disease-modifying therapy. Conclusions: The IPSS-M and AIPSS-MDS models provide more accurate survival prognoses than the IPSS-R, EuroMDS, and MLL models. The AIPSS-MDS model is a valid option for assessing risks for all patients with MDS, especially in resource-limited centers where molecular testing is not currently a standard clinical practice.
Asunto(s)
Azacitidina , Humanos , Azacitidina/administración & dosificación , Azacitidina/uso terapéutico , Masculino , Femenino , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/uso terapéutico , América del Sur , Esquema de Medicación , Persona de Mediana Edad , AncianoRESUMEN
Intensified pediatric chemotherapy regimens to treat adolescents and young adults (AYA) patients with Philadelphia negative acute lymphoblastic leukemia (ALL) have been associated with better outcomes. The local BFM 2009-based scheme complements the risk stratification assessing the measurable residual disease (MRD) along the induction phase with increasing levels of sensitivity. The present retrospective multicenter analysis included 171 AYA (15-40 years) patients treated accordingly between 2013 and 2019. Ninety-one percent obtained morphological complete remission, 67% a negative (<0.1%) MRD at day 33 (TP1), and 78% a negative (<0.01%) MRD at day 78 (TP2). The overall survival (OS) and the event-free survival (EFS) at 2 years were 62%±4.1 and 55%±4.1, respectively. The OS and EFS were significant better for prednisone responders, who achieved <10% BM blast at day 15, a negative MRD at TP1 or at TP2, and for low-risk patients. Age ≤30 years and WBC <30×109/L, particularly among B-phenotype, were also associated with longer OS. In the multivariable analyses, TP1 MRD positive (OS HR 2.8, 95% CI 1.4-5.7, p=0.004; EFS HR 3.0, 95% CI 1.6-5.7, p=0.001) and at TP2 (OS HR 2.6, 95% CI 1.3-5.3, p=0.012; EFS HR 2.6, 95% CI 1.3-5.1, p=0.006) were independently associated with earlier events. Age >30 years was also associated with a shorter survival (HR 3.1, 95% CI 1.3-7.5, p=0.014). Therefore, those 68 patients ≤30 years with TP1/TP2 negative MRD depicted a longer OS (2 years 85%±4.8). Based on our real-world data, the pediatric-based scheme is feasible in Argentina associated with better outcomes for younger AYA patients who achieved negative MRD at day 33 and 78.
Asunto(s)
Leucemia-Linfoma Linfoblástico de Células Precursoras , Humanos , Prednisona/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Inducción de Remisión , Riesgo , Estudios Retrospectivos , Neoplasia Residual/tratamiento farmacológico , Neoplasia Residual/genética , Pronóstico , Supervivencia sin Enfermedad , Estudios Multicéntricos como AsuntoRESUMEN
The use of tyrosine kinase inhibitors seems to restore the broadly compromised immune system described in chronic myeloid leukaemia (CML) patients at diagnosis leading to a re-activation of the effector-mediated immune surveillance. Here, we describe the expression dynamics of immune factors during the first year on imatinib therapy. Gene expression was evaluated in 132 peripheral blood samples from 79 CML patients, including 34 who were serially followed. An aliquot of the stored sample used to monitor BCR-ABL1 levels was retro-transcribed to cDNA and gene expression was quantified by real-time PCR. An elevated expression of ARG1 was observed at diagnosis, while TBET, CIITA, IL10 and TGFB1 were significantly decreased. Once on therapy, each gene displayed a particular behaviour. ARG1 normalized to control levels at 3 months only in optimal molecular responders and was identified as the major contributor to the difference among patients. TBET reached normal levels after 12 months in optimal responders and non-responders, regardless the Th1-response previously associated, and CIITA continued downregulated. IL10 and TGFB1 achieved normal levels early at 3 months in both groups, afterwards IL10 was sustained while TGFB1 was slightly increased after 1 year in responders. Our findings are in agreement with an immune re-activation after imatinib initiation; however, some immune mediators may require a longer exposition. The follow-up of novel and reliable biomarkers, such as ARG1, one of the principal mechanisms of myeloid-derived-suppressor cells to inhibit immune system, may be useful to deepen the characterization of early responder patients.
Asunto(s)
Arginasa/genética , Mesilato de Imatinib/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Adulto , Antineoplásicos/farmacología , Arginasa/metabolismo , Biomarcadores Farmacológicos/análisis , Biomarcadores Farmacológicos/sangre , Femenino , Proteínas de Fusión bcr-abl/genética , Expresión Génica , Humanos , Factores Inmunológicos/uso terapéutico , Interleucina-10/sangre , Interleucina-10/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/sangre , Masculino , Persona de Mediana Edad , Proteínas Nucleares/sangre , Proteínas Nucleares/genética , Inhibidores de Proteínas Quinasas/farmacología , Transactivadores/sangre , Transactivadores/genética , Transcriptoma/genética , Factor de Crecimiento Transformador beta1/sangre , Factor de Crecimiento Transformador beta1/genéticaAsunto(s)
Mastocitosis Sistémica , Síndromes Mielodisplásicos , Humanos , Lenalidomida/uso terapéutico , Mastocitosis Sistémica/complicaciones , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/tratamiento farmacológico , Mutación , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/tratamiento farmacológico , Fosfoproteínas/genética , Factores de Empalme de ARN/genéticaRESUMEN
Knowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil is limited. Our series of 280 patients depicted an older age at diagnosis (median 72 years old), 26% of aberrant karyotypes, and a prevalence of myelodysplastic (60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2 months for patients in CMML-0 (Ref.), 24.7 months for those in CMML-1 (HR = 2.0, p = 0.001), and 8.8 months for patients in CMML-2 (HR = 4.6, p < 0.001). In the CMML-0 category, median OS were different between myelodysplastic and myeloproliferative subtypes (63.7 vs 21.2 months, p < 0.001); however, no differences were observed within CMML-1 and CMML-2 subtypes (24.7 vs 23.7 months, p = 0.540, and 9.1 vs 8.2 months, p = 0.160). The prognostic impact of 24 variables and 7 prognostic systems was adjusted to the WHO 2016 after validating their usefulness. Multivariate analysis were performed, and the final model revealed Hb ≥ 8 -< 10g/dL (HR 1.7), Hb < 8g/dL (HR 2.8), poor karyotypes (HR 2.1), WHO 2016-CMML-1 (HR 2.1), and CMML-2 (HR 3.5) as independent adverse clinical parameters in our cohort with a borderline influence of platelets count < 50 × 109/L (HR 1.4). We could validate several scoring systems, the WHO 2016 proposal and its prognostic capability, along with accessible covariates, on predicting the outcome in our series of CMML patients from Latin America.
Asunto(s)
Leucemia Mielomonocítica Crónica/diagnóstico , Anciano , Argentina/epidemiología , Brasil/epidemiología , Femenino , Humanos , Leucemia Mielomonocítica Crónica/epidemiología , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Organización Mundial de la SaludAsunto(s)
Azacitidina , Bases de Datos Factuales , Síndromes Mielodisplásicos , Anciano , Azacitidina/administración & dosificación , Azacitidina/efectos adversos , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , América Latina/epidemiología , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/tratamiento farmacológico , Síndromes Mielodisplásicos/mortalidad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Trombocitopenia/sangre , Trombocitopenia/inducido químicamente , Trombocitopenia/mortalidadRESUMEN
Argentina is a country characterized by a heterogeneous distribution of its population, its economic resources and, consequently, access to health services, which could affect the diagnosis and treatment of patients with myelodysplastic syndromes. Based on the increasing complexity to arrive at the diagnosis, estimate the risk and indicate an adequate treatment, we have conducted a survey of twenty-three questions to evaluate patterns of clinical practice. The questionnaire was distributed among 850 hematologists registered at the XXII Argentine Congress of Hematology, and 195 (22.9%) were answered; 40.0% report that < 75% of their patients access the karyotype, bone marrow histology and flow cytometry. This access decreases significantly due to low health coverage (OR 6.3), in the adult population (OR 3.8), when the cytogenetic study is derived (OR 3.2) and outside the metropolitan area of Buenos Aires (OR 2.4). The respondents avoid oncological terminologies (77.0%) when introducing the diagnosis and use the international prediction system or its review (74.2%) to stage risk. However, they prioritize age when selecting treatment and pediatricians preferentially recommend the transplantation of hematopoietic precursors. Most of the haematologists have prescribed the recommended treatments, whose suspensions were related to lack of response (62.7%), with reduced participation in clinical trials (8.9%). Therefore, they report heterogeneity in the access to complementary diagnostic tools with differences at the time of indicating a treatment, depending on the age of their patients without apparent limitations in their prescription.
La Argentina es un país caracterizado por una distribución heterogénea de su población, de sus recursos económicos y, consiguientemente, del acceso a los servicios de salud, lo cual podría afectar el diagnóstico y tratamiento de los pacientes con síndromes mielodisplásicos. Basados en la complejidad creciente para arribar al diagnóstico, estimar el riesgo e indicar un tratamiento adecuado, hemos conducido una encuesta de veintitrés preguntas para evaluar patrones de práctica clínica. El cuestionario se distribuyó entre los 850 hematólogos argentinos inscriptos al XXII Congreso Argentino de Hematología y 195 (22.9%) fueron contestados. El 40.0% refieren que < 75% de sus pacientes acceden al cariotipo, histología de la médula ósea y citometría de flujo. Este acceso disminuye significativamente por una baja cobertura sanitaria (OR 6.3), en población adulta (OR 3.8), al derivar el estudio citogenético (OR 3.2) y fuera del área metropolitana de Buenos Aires (OR 2.4). Los encuestados evitan terminologías oncológicas (77.0%) al introducir el diagnóstico y utilizan el sistema internacional de predicción o su revisión (74.2%) para estadificar riesgo. Sin embargo, éstos priorizan la edad al seleccionar tratamiento y los pediatras indican preferentemente el trasplante de precursores hematopoyéticos. La mayoría de los hematólogos ha prescripto los tratamientos recomendados, cuyas suspensiones se relacionaron con falta de respuesta (62.7%), con participación reducida en ensayos clínicos (8.9%). Por ende, refieren heterogeneidad en el acceso a las herramientas diagnósticas complementarias con diferencias al momento de indicar un tratamiento, dependiendo de la edad de sus pacientes, sin limitaciones aparentes en su prescripción.
Asunto(s)
Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/terapia , Práctica Profesional , Argentina , Protocolos Clínicos , Encuestas Epidemiológicas , Humanos , Encuestas y CuestionariosRESUMEN
La Argentina es un país caracterizado por una distribución heterogénea de su población, de sus recursos económicos y, consiguientemente, del acceso a los servicios de salud, lo cual podría afectar el diagnóstico y tratamiento de los pacientes con síndromes mielodisplásicos. Basados en la complejidad creciente para arribar al diagnóstico, estimar el riesgo e indicar un tratamiento adecuado, hemos conducido una encuesta de veintitrés preguntas para evaluar patrones de práctica clínica. El cuestionario se distribuyó entre los 850 hematólogos argentinos inscriptos al XXII Congreso Argentino de Hematología y 195 (22.9%) fueron contestados. El 40.0% refieren que < 75% de sus pacientes acceden al cariotipo, histología de la médula ósea y citometría de flujo. Este acceso disminuye significativamente por una baja cobertura sanitaria (OR 6.3), en población adulta (OR 3.8), al derivar el estudio citogenético (OR 3.2) y fuera del área metropolitana de Buenos Aires (OR 2.4). Los encuestados evitan terminologías oncológicas (77.0%) al introducir el diagnóstico y utilizan el sistema internacional de predicción o su revisión (74.2%) para estadificar riesgo. Sin embargo, éstos priorizan la edad al seleccionar tratamiento y los pediatras indican preferentemente el trasplante de precursores hematopoyéticos. La mayoría de los hematólogos ha prescripto los tratamientos recomendados, cuyas suspensiones se relacionaron con falta de respuesta (62.7%), con participación reducida en ensayos clínicos (8.9%). Por ende, refieren heterogeneidad en el acceso a las herramientas diagnósticas complementarias con diferencias al momento de indicar un tratamiento, dependiendo de la edad de sus pacientes, sin limitaciones aparentes en su prescripción.
Argentina is a country characterized by a heterogeneous distribution of its population, its economic resources and, consequently, access to health services, which could affect the diagnosis and treatment of patients with myelodysplastic syndromes. Based on the increasing complexity to arrive at the diagnosis, estimate the risk and indicate an adequate treatment, we have conducted a survey of twenty-three questions to evaluate patterns of clinical practice. The questionnaire was distributed among 850 hematologists registered at the XXII Argentine Congress of Hematology, and 195 (22.9%) were answered; 40.0% report that < 75% of their patients access the karyotype, bone marrow histology and flow cytometry. This access decreases significantly due to low health coverage (OR 6.3), in the adult population (OR 3.8), when the cytogenetic study is derived (OR 3.2) and outside the metropolitan area of Buenos Aires (OR 2.4). The respondents avoid oncological terminologies (77.0%) when introducing the diagnosis and use the international prediction system or its review (74.2%) to stage risk. However, they prioritize age when selecting treatment and pediatricians preferentially recommend the transplantation of hematopoietic precursors. Most of the haematologists have prescribed the recommended treatments, whose suspensions were related to lack of response (62.7%), with reduced participation in clinical trials (8.9%). Therefore, they report heterogeneity in the access to complementary diagnostic tools with differences at the time of indicating a treatment, depending on the age of their patients without apparent limitations in their prescription.
Asunto(s)
Humanos , Práctica Profesional , Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/terapia , Argentina , Protocolos Clínicos , Encuestas y Cuestionarios , Encuestas EpidemiológicasRESUMEN
There are previously reported data describing differences between Asian and European patients with Myelodysplastic Syndromes (MDS), few direct comparisons based on cancer registration characteristics or using cohorts to validate scoring systems. This is the first study from South-America, which attempts to describe demographic, clinical features, and outcome of MDS patients. We retrospectively analyzed 1,080 patients with de novo MDS from Argentina (635), Brazil (345), and Chile (100). Chilean patients were younger (P = 0.001) with female preponderance (P = 0.071). Brazilian series showed a higher predominance of RARS subtype regarding FAB and WHO classifications (P < 0.001). Hemoglobin levels were significantly lower in Brazilian and Chilean series (P < 0.001), and Chilean series also showed a lower platelet count (P = 0.028), with no differences concerning the neutrophil count, % BM blast, and the distribution of cytogenetic risk groups (P > 0.05). Chilean series depicted a lower overall survival (OS; 35 months vs. 56 months-Argentine; 55 months-Brazil, P = 0.030), which was consistent with a higher predominance of the high-risk group according both to the IPSS and IPSS-R (P = 0.046 and P < 0.001). The IPSS-R system and its variables showed a good reproducibility to predict clinical outcome for the whole South-American population. Epidemiological and clinical characteristics, distribution among prognostic subgroups, the OS, and the access to disease modifying therapies were more similar between Argentinean and Brazilian compared with Chilean MDS series. This will need further analysis in a larger group of patients. Descriptive and comparative studies are necessary to establish epidemiological features useful for public health attitudes to generate suitable therapeutic schemes.
Asunto(s)
Síndromes Mielodisplásicos/mortalidad , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/terapia , Estudios Retrospectivos , América del Sur/epidemiologíaAsunto(s)
Clasificación Internacional de Enfermedades/tendencias , Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Argentina/epidemiología , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/mortalidad , Pronóstico , Estudios Retrospectivos , Tasa de Supervivencia/tendencias , Adulto JovenAsunto(s)
Análisis Citogenético , Síndromes Mielodisplásicos/genética , Femenino , Humanos , MasculinoRESUMEN
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematological diseases characterized by refractory cytopenia(s). MDS patients show increased levels of tumor necrosis factor alpha (TNFα) which is a multifunctional proinflammatory cytokine. The aim of this work is to examine the presence of -308A/G TNFα variants and to analyze whether it is associated with clinical parameters in a cohort of 101 Argentinean de novo MDS patients. The A/A+A/G genotype at TNFα -308 was overrepresented 2-fold in our population (p=0.0499, odds ratio-OR: 2.107) and these differences were more evident in RA-FAB subtype (p=0.0424, OR: 2.502). The presence of the high expressing -308A allele was associated with lower hemoglobin level (8.3 vs 9.9g/dL; p=0.0206), reduced platelet counts (89,000 vs 130,000/µL; p=0.0381) and younger age (59 vs 68years; p=0.0122) at diagnosis. Also, these patients showed 3.8-fold higher risk of transfusion requirement (76% vs 46%, p=0.0105) during the follow up. In conclusion, the presence of an inherited -308A TNFα, which increases its transcription level, was associated with the MDS phenotype in our cohort of Argentine MDS patients. Also, an overexpression of TNFα may promote an underlying proinflammatory state that cooperates with intrinsic defects within MDS progenitors to increase the severity of certain phenotypic features of the disease.
Asunto(s)
Anemia/complicaciones , Anemia/genética , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/genética , Trombocitopenia/complicaciones , Trombocitopenia/genética , Factor de Necrosis Tumoral alfa/genética , Anciano , Alelos , Femenino , Estudios de Asociación Genética , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Myelodysplastic syndromes (MDS) include a group of heterogeneous hematological disorders with a variable risk of leukemic evolution and short survival. Around 40-50% of patients show abnormal karyotypes that are mostly characterized by monosomies or deletions. Cytogenetic findings are an independent prognostic factor and the International prognostic scoring system (IPSS) differentiates three cytogenetic categories, despite the Intermediate one being heterogeneous. The aim of this study, including 421 Argentinean patients with primary MDS, is to characterize the cytogenetic profile, to test its prognostic value and to compare partial and monosomal karyotypes against other cytogenetic findings. An abnormal karyotype (median survival: 26 months) was observed in 176 patients. The presence of complex karyotypes, number of alterations, and the IPSS cytogenetic groups showed significant differences for predicting outcome. Behavior of patients with isolated deletions (median survival: 49 months) did not differ from those with normal karyotype (56 months, P = 0.654) or Good prognostic findings (43 months, P = 0.371). However, a worse prognosis was observed when another alteration was added (31 months, P = 0.043). Karyotypes with autosomal monosomies (median survival: 16 months) had a prognostic impact similar to other Poor cytogenetic findings (17 months, P = 0.626). In our population classified according to French-American-British (FAB) or World Health Organization (WHO), this new categorization of cytogenetic abnormalities, recognizing three different risk groups, showed an independent prognostic impact and a better discriminating power than the IPSS categories. It can be concluded that all isolate deletions (excluding 7q-) are good prognostic findings and all monosomies (excluding Y chromosome loss) are bad indicators.
Asunto(s)
Cromosomas Humanos/genética , Monosomía , Síndromes Mielodisplásicos/genética , Síndromes Mielodisplásicos/mortalidad , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Argentina/epidemiología , Deleción Cromosómica , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de SupervivenciaRESUMEN
Los Síndromes Mielodisplásicos (SMD) comprenden un grupo heterogéneo de desórdenes hematológicos con riesgo de evolución leucémica. En este trabajo se evaluó el valor pronóstico del cariotipo al momento del diagnóstico, teniendo en cuenta el International Prognostic Scoring System (IPSS). Dicho puntaje propone 3 grupos pronósticos para la variable citogenética: Bueno (cariotipo normal, del(5q), del(20q) o -Y), Intermedio (+8 y misceláneas) y Malo (-7/del(7q) o alteraciones complejas). En este estudio se evaluaron 198 pacientes (95 AR, 13 AS, 43 AREB, 23 AREBt y 24 LMMC) distribuidos, de acuerdo al IPSS en: 60 Bajo riesgo, 76 Intermedio 1, 32 Intermedio 2 y 30 Alto riesgo (media de seguimiento: 28 meses). Los resultados citogenéticos de médula ósea se agruparon en: 126 Bueno, 41 Intermedio y 31 Malo, con una mediana de Sobrevida de 60, 34 y 28 meses (p=0.013) y una Evolución Leucémica (25porciento) de 46, 19 y 5 meses (p<0.001), respectivamente. El cruzamiento entre los grupos citogenéticos y el IPSS mostró que el 84 porciento de los pacientes pertenecientes al grupo citogenético Bueno correspondían al riesgo Bajo e Intermedio-l, el 61 porciento del grupo citogenético Intermedio presentaban riesgo Intermedio-l; mientras que, el 84 porciento perteneciente al grupo citogenético Malo pertenecían a los grupos de riesgo Intermedio-2 y Alto. Estos datos muestran una importante asociación (p<0.001) entre el estudio citogenético y los grupos de riesgo determinados por el IPSS. Lo cual indica la importancia del cariotipo, aparte del porcentaje de blastos y las citopenias, para individualizar grupos pronósticos en los SMD.
Asunto(s)
Análisis Citogenético , Enfermedades HematológicasRESUMEN
Los Síndromes Mielodisplásicos (SMD) comprenden un grupo heterogéneo de desórdenes hematológicos con riesgo de evolución leucémica. En este trabajo se evaluó el valor pronóstico del cariotipo al momento del diagnóstico, teniendo en cuenta el International Prognostic Scoring System (IPSS). Dicho puntaje propone 3 grupos pronósticos para la variable citogenética: Bueno (cariotipo normal, del(5q), del(20q) o -Y), Intermedio (+8 y misceláneas) y Malo (-7/del(7q) o alteraciones complejas). En este estudio se evaluaron 198 pacientes (95 AR, 13 AS, 43 AREB, 23 AREBt y 24 LMMC) distribuidos, de acuerdo al IPSS en: 60 Bajo riesgo, 76 Intermedio 1, 32 Intermedio 2 y 30 Alto riesgo (media de seguimiento: 28 meses). Los resultados citogenéticos de médula ósea se agruparon en: 126 Bueno, 41 Intermedio y 31 Malo, con una mediana de Sobrevida de 60, 34 y 28 meses (p=0.013) y una Evolución Leucémica (25porciento) de 46, 19 y 5 meses (p<0.001), respectivamente. El cruzamiento entre los grupos citogenéticos y el IPSS mostró que el 84 porciento de los pacientes pertenecientes al grupo citogenético Bueno correspondían al riesgo Bajo e Intermedio-l, el 61 porciento del grupo citogenético Intermedio presentaban riesgo Intermedio-l; mientras que, el 84 porciento perteneciente al grupo citogenético Malo pertenecían a los grupos de riesgo Intermedio-2 y Alto. Estos datos muestran una importante asociación (p<0.001) entre el estudio citogenético y los grupos de riesgo determinados por el IPSS. Lo cual indica la importancia del cariotipo, aparte del porcentaje de blastos y las citopenias, para individualizar grupos pronósticos en los SMD.(AU)